Albert MH, Sirin M, Hoenig M, Hauck F, Schuetz C, Bhattacharyya R, Stepensky P, Jacoby E, Güngör T, Beier R, Schulz A. Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders. Bone Marrow Transplant. 2021;56(9):2248–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petinati N, Drize N, Sats N, Risinskaya N, Sudarikov A, Drokov M, Dubniak D, Kraizman A, Nareyko M, Popova N, Firsova M. Recovery of donor hematopoiesis after graft failure and second hematopoietic stem cell transplantation with intraosseous administration of mesenchymal stromal cells. Stem Cells Int. 2018;10:2018.

Google Scholar 

Locatelli F, Lucarelli B, Merli P. Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Pharmacother. 2014;15(1):23–36.

Article  CAS  PubMed  Google Scholar 

Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48:537–43.

Article  CAS  PubMed  Google Scholar 

Valcarcel D, Sureda A. Graft failure. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook. EBMT; 2019, pp. 307–13.

Olsson RF, Logan BR. Chaudhury S, Zhu X, Akpek G, Bolwell BJ, et al. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia. 2015;29(8):1754–62.

Masouridi-Levrat S, Simonetta F, Chalandon Y. Immunological basis of bone marrow failure after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;16(7):362.

Google Scholar 

Gyurkocza B, Cao TM, Storb R, et al. Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. Biol Blood Marrow Transp. 2009;15:1314–22.

Article  CAS  Google Scholar 

Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American society for transplantation and cellular therapy. Transp Cell Ther. 2021;27(8):642–9.

CAS  Google Scholar 

Carreras E, Dufour C, Mohty M, Kröger N (2019) The EBMT Handbook. Hematopoietic stem cell transplantation and cellular therapies. Cham, Springer

Cluzeau T, Lambert J, Raus N, et al. Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI. Bone Marrow Transplant. 2016;51:687–91.

Article  CAS  PubMed  Google Scholar 

Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73:606–13.

Article  CAS  PubMed  Google Scholar 

McCann SR, Bacigalupo A, Gluckman E, Hinterberger W, Hows J, Ljungman P, et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the aplastic anaemia working party of the European bone marrow transplant group. Bone Marrow Transplant. 1994;13:233–7.

CAS  PubMed  Google Scholar 

Kongtim P, Cao K, Ciurea SO. Donor specific anti-HLA antibody and risk of graft failure in haploidentical stem cell transplantation. Adv Hematol. 2016;2016:4025073.

Article  PubMed  PubMed Central  Google Scholar 

Booth C, Veys P. T cell depletion in paediatric stem cell transplantation. Clin Exp Immunol. 2013;172:139–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gyger M, Baron C, Forest L, et al. Quantitative assessment of hematopoietic chimerism after allogeneic bone marrow transplantation has predictive value for the occurrence of irreversible graft failure and graft-vs.-host disease. Exp Hematol. 1998;26(5):426–34.

CAS  PubMed  Google Scholar 

Lapidot T, et al. Enhancement of T-cell-depleted bone marrow allografts in the absence of graft-versus-host disease is mediated by CD8++ CD4- and not by CD8+- CD4++ thymocytes. Blood. 1992;80(9):2406–11.

Article  CAS  PubMed  Google Scholar 

Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med. 1993;178(2):703–12.

Article  CAS  PubMed  Google Scholar 

Gandy KL, et al. CD8+TCR+ and CD8+TCR- cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity. 1999;11(5):570–9.

Article  Google Scholar 

Michael M, Shimoni A, Nagler A. Regulatory T cells in allogeneic stem cell transplantation. Clin Dev Immunol. 2013;2013: 608951.

Article  PubMed  PubMed Central  Google Scholar 

Barao I, Hanash AM, Hallett W, Welniak LA, Sun K, Redelman D, et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 2006;103(14):5460–5. https://doi.org/10.1073/pnas.0509249103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, Romagnoli P, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med. 2008;14(1):88–92. https://doi.org/10.1038/nm1688.

Article  CAS  PubMed  Google Scholar 

Pilat N, Klaus C, Gattringer M, Jaeckel E, Wrba F, Golshayan D, et al. Therapeutic efficacy of polyclonal tregs does not require rapamycin in a low- dose irradiation bone marrow transplantation model. Transplantation. 2011;92(3):280–8. https://doi.org/10.1097/TP.0b013e3182241133.

Article  PubMed  Google Scholar 

Müller AM, Poyser J, Küpper NJ, Burnett C, Ko RM, Kohrt HE, et al. Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment. Blood. 2014;123(18):2882–92. https://doi.org/10.1182/blood-2013-10-530212.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gill S, Olson JA, Negrin RS. Natural killer cells in allogeneic transplantation: effect on engraftment, graft-versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transplant. 2009;15(7):765–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palmer JM, Rajasekaran K, Thakar MS, Malarkannan S. Clinical relevance of natural killer cells following hematopoietic stem cell transplantation. J Cancer. 2013;4(1):25.

Article  CAS  PubMed  Google Scholar 

Ferrà C, Sanz J, Díaz-Pérez MA, Morgades M, Gayoso J, Cabrera JR, Villaescusa T, Sampol MA, Fernández-Avilés F, Solano C, Ortín M. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leuk Lymphoma. 2015;56(3):656–62.

Article  PubMed  Google Scholar 

Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant. 2008;41(2):207–14.

Article  CAS  PubMed  Google Scholar 

Locatelli F, Bauquet A, Palumbo G, Moretta F, Bertaina A. Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Immunol Lett. 2013;155(1–2):21–3.

Article  CAS  PubMed  Google Scholar 

Rocha V, Gluckman E. Clinical use of umbilical cord blood hematopoietic stem cells. Biol Blood Marrow Transplant. 2006;12(1):34–41.

Article  PubMed  Google Scholar 

Locatelli F, Pende D, Maccario R, Mingari MC, Moretta A, Moretta L. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin Immunol. 2009;133(2):171–8.

Article  CAS  PubMed  Google Scholar 

Sun YQ, Wang Y, Wang FR, Yan CH, Cheng YF, Chen YH, Zhang YY, Han TT, Han W, Suo P, Xu LP. Graft failure in patients with hematological malignancies: a successful salvage with a second transplantation from a different haploidentical donor. Front Med. 2021:721.

Bramanti S, Calafiore V, Longhi E, Mariotti J, Crespiatico L, Sarina B, De Philippis C, Nocco A, Santoro A, Castagna L. Donor-specific anti-HLA antibodies in haploidentical stem cell transplantation with post-transplantation cyclophosphamide: risk of graft failure, poor graft function, and impact on outcomes. Biol Blood Marrow Transplant. 2019;25(7):1395–406.

Article  CAS  PubMed  Google Scholar 

Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, López AA, Yap DY, Popat U, Rondon G, Lichtiger B. Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(8):1392–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Locatelli F. Improving cord blood transplantation in children. Br J Haematol. 2009;147(2):217–26.

Article  PubMed  Google Scholar 

Rocha V, Gluckman E. Eurocord‐Netcord registry and European Blood and Marrow Transplant group. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft‐and transplantation‐related factors. British J Haematol. 2009;147(2):262–74.

Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graftfailure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant. 2002;29:545–52.

Article  CAS  PubMed  Google Scholar 

McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños- Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125:3024–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruggeri A. Optimizing cord blood selection. Hematology. 2019;2019(1):522–31.

Article  PubMed  PubMed Central  Google Scholar 

Gladstone DE, Bettinotti MP. HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities. Hematology. 2017;2017(1):645–50.